NASDAQ:FGENFibroGen Stock Price, Forecast & News

FibroGen's stock was trading at $35.40 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FGEN shares have increased by 22.9% and is now trading at $43.50. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for FibroGen.

FibroGen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for FibroGen.

FibroGen Inc (NASDAQ:FGEN) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.50. The biopharmaceutical company earned $24.40 million during the quarter, compared to analysts' expectations of $72.58 million. FibroGen had a negative return on equity of 19.32% and a negative net margin of 42.75%. The business's revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.53) earnings per share. View FibroGen's earnings history.

5 equities research analysts have issued 12-month price objectives for FibroGen's stock. Their forecasts range from $40.00 to $80.00. On average, they anticipate FibroGen's share price to reach $57.60 in the next twelve months. This suggests a possible upside of 32.4% from the stock's current price. View analysts' price targets for FibroGen.

Media headlines about FGEN stock have trended negative on Sunday, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. FibroGen earned a daily sentiment score of -2.2 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View the latest news about FibroGen.

Some companies that are related to FibroGen include Merck KGaA (MKGAF), Beigene (BGNE), GALAPAGOS NV/S (GLPG), GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT), Teva Pharmaceutical Industries (TEVA), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Elanco Animal Health (ELAN), Mylan (MYL), ACADIA Pharmaceuticals (ACAD) and Perrigo (PRGO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

(FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FGEN stock can currently be purchased for approximately $43.50.

FibroGen has a market capitalization of $3.88 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. FibroGen employs 461 workers across the globe.

The official website for FibroGen is www.fibrogen.com.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]